Skip to content

Circles

S

Silexion Therapeutics Corp

SLXN· Nasdaq

S

SLXNSilexion Therapeutics Corp

SLXNSilexion Therapeutics Corp·Earnings record

Q1 2024

Source filing unavailable

Previous · Q3 2023 Next · Q2 2024

Q1 2024 · —

Revenue—

Net Income

-$1.42M

no prior Q1 2023 on file

EPS Diluted

$12.29

no prior Q1 2023 on file

Operating Income-$1,250,000—

Operating Cash Flow-$1,752,000—

Free Cash Flowderived-$1,758,000—

Same quarter

no prior Q1 2023 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Filing lag

Quarterly history

Q2 ’23 Q3 ’23Q1 ’24Q2 ’24 Q3 ’24 Q4 ’24^d Q1 ’25 Q2 ’25 Q3 ’25…

Silexion Therapeutics Corp · CIK 2022416 · Engraved from SEC EDGAR

Thaler ResearchEngraved from SEC EDGAR© 2026 Thaler. All rights reserved.Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Platform

Using AI API SDKs CLI

Research

News Listen Earnings Insiders Holders Compare Metrics

Screener Watchlists Pies Notes Your companies

Learn

Thaler

Thaler Agent Promise Provenance Circles Account Terms Privacy